Ziopharm Oncology (ZIOP) is in talks with prospective partners to market palifosfamide, which...
Wednesday, February 13, 10:07 AM ETZiopharm Oncology (ZIOP) is in talks with prospective partners to market palifosfamide, which appears to have performed well in patients with metastatic soft tissue sarcoma in a Phase III trial. Ziopharm may sign a deal before the full study data is known, although the greater likelihood is after its release in March. Ziopharm's shares shot up 18% yesterday on news of the trial, and are now +2.1%.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles